1 Introduction GLP-1 agonists for obesity treatment have imposed a substantial cost burden on the U.S. healthcare system; in response, the Trump administration has negotiated with the two main manufacturers (Novo Nordisk and Eli Lilly) to lower prices significantly. Under their agreement, Medicare and Medicaid prices decrease to $245 per month with a $50 patient copay [1].
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile